Cost effectiveness of genotype-guided antiplatelet therapy in Asian ischemic stroke patients: ticagrelor as an alternative to clopidogrel in patients with CYP2C19 loss …
Background Patients with ischemic stroke are often treated with clopidogrel monotherapy as
part of secondary stroke prevention. The prevalence of loss of function (LOF) mutations in …
part of secondary stroke prevention. The prevalence of loss of function (LOF) mutations in …
Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack
K Narasimhalu, J Chan, YK Ang… - … Journal of Stroke, 2024 - journals.sagepub.com
Background: Patients with minor ischemic stroke or transient ischemic attacks (TIAs) are
often treated with dual antiplatelet therapy regimens as part of secondary stroke prevention …
often treated with dual antiplatelet therapy regimens as part of secondary stroke prevention …
CYP2C19 genotype-guided antiplatelet therapy among Asian patients with ischaemic stroke
We read with interest the cost-effectiveness study by Narasimhalu et al.[1], which evaluated
the cost effectiveness of CYP2C19 genotype-guided antiplatelet therapy in an Asian …
the cost effectiveness of CYP2C19 genotype-guided antiplatelet therapy in an Asian …